Edited by
Alex Adjei, Mayo Clinic, Rochester, Minnesota, U.S.A.
John Buolamwini, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.
Description
This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents,
and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This
book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets,
as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the
new, relatively non-cytotoxic anticancer agents.
At present, there is no book that provides such an integration of basic and clinical
studies of novel anticancer agents, covering both drug discovery and translational research extensively.
Audience:
Researchers in pharmacology and oncology (both government and industry), clinical oncologists who are in clinical research in universities
or in industry, anticancer drug discovery and development scientists, research libraries, postgraduate students, fellows and general
oncology practicing physicians.
